Colorectal Neoplasms Clinical Trial
Official title:
Anastomotic Leakage and Enhanced Recovery Pathways After Colorectal Surgery: the Italian ColoRectal Anastomotic Leakage Study Group (iCral 2)
Prospective observational multicenter study on the influence of adherence to enhanced recovery pathways on early outcomes (anastomotic leakage, morbidity, mortality, readmission, reoperation rates and length of postoperative stay) after elective colorectal surgery in Italy.
BACKGROUND
Anastomotic leakage (AL) is a dreaded major complication after colorectal surgery. The
overall incidence of anastomotic dehiscence and subsequent leaks is 2 to 7 percent when
performed by experienced surgeons. The lowest leak rates are found with ileocolic anastomoses
(1 to 3 percent) and the highest occur with coloanal anastomosis (10 to 20 percent). Leaks
usually become apparent between five and seven days postoperatively. Almost half of all leaks
occur after the patient has been discharged, and up to 12 percent occur after postoperative
day (POD) 30. Late leaks often present insidiously with low-grade fever, prolonged ileus, and
nonspecific symptoms attributable to other postoperative infectious complications. Small,
contained leaks present later in the clinical course and may be difficult to distinguish from
postoperative abscesses by radiologic imaging, making the diagnosis uncertain and
underreported.
There is no uniform definition of an anastomotic dehiscence and leak. In a review of 97
studies, as an example, 56 different definitions of an anastomotic leak were used. The
majority of reports define an anastomotic leak using clinical signs, radiographic findings,
and intraoperative findings. The clinical signs include: Pain, Fever, Tachycardia,
Peritonitis, Feculent drainage, Purulent drainage. The radiographic signs include: Fluid
collections, Gas containing collections. The intraoperative findings include: Gross enteric
spillage, Anastomotic disruption.
Risk factors for a dehiscence and leak are classified according to the site of the
anastomosis (extraperitoneal or intraperitoneal). A prospective review of 1598 patients
undergoing 1639 anastomotic procedures for benign or malignant colorectal disease found a
significantly increased risk of anastomotic leak with extraperitoneal compared with
intraperitoneal anastomoses (6.6 versus 1.5 percent; 2.4 percent overall).
Major risk factors for an extraperitoneal AL include: The distance of the anastomosis from
the anal verge (Patients with a low anterior resection and an anastomosis within 5 cm from
the anal verge are the highest risk group for an anastomotic leak), Anastomotic ischemia,
Male gender, Obesity.
Major risk factors for an intraperitoneal AL include: American Society of Anesthesiologists
(ASA) score Grade III to V, Emergent surgery, Prolonged operative time, Hand-sewn ileocolic
anastomosis.
Controversial, inconclusive, or pertinent negative associations between the following
variables and AL have been reported: Neoadjuvant radiation therapy, Drains, Protective stoma,
Hand-sewn colorectal anastomosis, Laparoscopic procedure, Mechanical bowel preparation,
Nutritional status, Perioperative corticosteroids.
Enhanced Recovery After Surgery (ERAS) programs for colorectal surgery have been extensively
studied during the last 20 years. It is now clear that they offer a consistent reduction of
overall morbidity rates, postoperative length of stay and costs, and that there is a clear
dose-effect relation between adherence to at least 60-70% of the program items and these
outcomes. On the other hand, little is known concerning the potential benefit of ERAS
programs over AL rates or if adherence to specific items of the program may reduce AL rates.
Therefore, the investigators planned this study to prospectively evaluate AL rates after
colorectal resections and their interaction with known risk factors and ERAS program items.
METHODS
Prospective enrollment from January to December 2019 in 41 Italian surgical centers. All
patients undergoing elective colorectal surgery with anastomosis will be included in a
prospective database after having provided a written informed consent. A total of 1,750
patients is expected based on a mean of 43 cases/year per center.
Outcome measures
1. Preoperative risk factors of anastomotic leakage (age, gender, obesity, nutritional
status, diabetes, cardiovascular disease, chronic liver disease, renal failure,
inflammatory bowel disease, perioperative steroid therapy, ASA class I-II vs III)
2. Operative parameters (approach, procedure, anastomotic technique, length of operation,
disease stage)
3. ERAS program items (prehabilitation, counseling, nutritional evaluation,
immuno-nutrition, deep venous thrombosis prophylaxis, antibiotic prophylaxis, bowel
preparation, preoperative carbohydrates load, standardized anesthesia protocol,
restrictive i.v. fluid administration, control of body temperature, nausea and vomit
prophylaxis, multimodal approach to opioid-sparing pain control, restrictive use of
surgical drains, laparoscopic surgery, removal of nasogastric tubes before reversal of
anesthesia, early removal of urinary catheter, early mobilization, early oral intake of
fluids and solids, use of chewing gums and laxatives, intake of protein-rich nutritional
supplements, prepare for early discharge, audit).
Endpoints
1. Anastomotic leakage rate
2. Minor and major complications
3. Length of postoperative hospital stay
4. Readmission and reoperation rates Recorded data and follow-up Potential patient-specific
and intraoperative risk factors will be recorded: gender, body mass index, nutritional
status according to the Mini Nutritional Assessment short-form, surgical indication
(cancer, polyps, chronic inflammatory bowel disease, diverticular disease), preoperative
albuminemia, use of steroids, renal failure and dialysis, cardiovascular or respiratory
disease, American Society of Anesthesia class, bowel preparation (decision made by
operating surgeon), laparoscopy or laparotomy, level of anastomosis and technique
(mechanical or hand-sewn, intra- or extra-corporeal), operative time, presence of
drainage, and perioperative blood transfusion(s). During the postoperative period,
patients will be examined by the attending surgeon daily. Fever (central temperature >
38 °C), pulse, abdominal signs, bowel movements, volume and aspect of drainage (if
present) will be recorded daily. The attending surgeon will make any decision for
complementary exams and imaging according to his own criteria. The rate of any
complication will be calculated and graded including all leaks (independently of
clinical significance), wound infection (according to the definitions of the Centers for
Disease Control and Prevention and wound culture), pneumonia (clinical symptoms, and
physical and radiological examinations), central line infection (positive blood
culture), urinary tract infection (positive urine culture with bacterial count ).
Patients will be followed-up in the outpatient clinic up to 6 weeks after discharge from
the hospital.
Main endpoint is anastomotic dehiscence (intended as any deviation from the planned
postoperative course related to the anastomosis, or presence of pus or enteric contents
within the drains, presence of abdominal or pelvic collection in the area of the anastomosis
on postoperative CT scan, performed at the discretion of the attending surgeon, leakage of
contrast through the anastomosis during enema or evident anastomotic dehiscence at
reoperation for postoperative peritonitis). Thus, all detected leaks will be considered
independently of clinical significance. No imaging will be performed routinely in order to
search for leakage.
Secondary endpoints are morbidity and mortality rates, postoperative length of stay,
readmission and reoperation rates.
After anonymization, all data of each single case will be prospectively uploaded by every
local investigator on a protected web-based database. Thereafter, all data will be
incorporated into a spreadsheet (MS Excel) for data analysis, checking for any discrepancy,
that will be addressed and solved through strict cooperation between chief investigator, data
manager and participating center.
Statistical Analysis Quantitative values will be expressed as mean ± standard deviation,
median and range; categorical data with percentage frequencies. Mean values of duration of
stay will be compared according to the presence or absence of fistulas using Student's
two-sided t test (allowing for heterogeneity of variances) or with a non-parametric
Mann-Whitney test. Both univariate analysis and multivariate analysis will be performed to
assess risk factors for leakage and overall complications. The odds ratio (OR) will be
presented followed by its 95% confidence interval (95% CI). For all statistical tests the
significant level is fixed at p < .05.
Statistical analyses will be carried out using STATA software (Stata Corp. College Station,
Texas, USA).
Sample size Considering that adherence to 70% of the items of an ERAS program determines a
significant reduction in surgical complications after colorectal surgery, an estimation of
the OR for AL and ERAS program adherence at 70% of the items is equal to 0.55 (95% c.i.
0.36-0.87); assuming a maximum error equal to 0.04, the required sample size is n=1,748
(about 874 cases per arm expected in low vs high adherence to ERAS programs).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04552093 -
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
|
Phase 2/Phase 3 | |
Completed |
NCT04192565 -
A Prospective Investigation of the ColubrisMX ELS System
|
N/A | |
Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
Recruiting |
NCT03561350 -
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
|
||
Recruiting |
NCT06128798 -
Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery.
|
N/A | |
Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
Completed |
NCT03631407 -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
|
Phase 2 | |
Withdrawn |
NCT04192929 -
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT02889679 -
Underwater Resection of Non-pedunculated Colorectal Lesions
|
N/A | |
Terminated |
NCT02842580 -
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02564835 -
Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer
|
N/A | |
Completed |
NCT02149108 -
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
|
Phase 3 | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02599103 -
The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects
|
N/A | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Completed |
NCT01669109 -
Hatha Yoga for Patients With Colorectal Cancer
|
N/A | |
Recruiting |
NCT01428752 -
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
|
N/A | |
Completed |
NCT01978717 -
General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer
|
N/A | |
Completed |
NCT01877018 -
Colorectal Cancer Screening in Primary Care
|
N/A |